KiOmed Pharma secures €18 Million to accelerate development of innovative medical solutions
Liège - Herstal
KiOmed Pharma announces it has secured €18 million in funding to drive the the expansion of its cutting-edge portfolio of medical devices. This investment will primarily support the growth of KiOmedine®, the company’s groundbreaking treatment for knee osteoarthritis, while also accelerating advancements in aesthetic medicine and ophthalmology.
“This milestone marks a significant step forward for the company. It enables us to scale internationally while strengthening our industrial and scientific expertise,” says François Blondel Founder and Executive Chairman of KiOmed Pharma.
A proven treatment expanding globally
KiOmedine®, formulated from a highly purified, non-animal-derived chitosan, provides a novel alternative for the symptomatic treatment of knee osteoarthritis. To date, it has improved mobility and quality of life for over 35,000 patients, particularly those with active lifestyles or limited treatment options.
The product is currently marketed in over ten European countries and in the Middle East. Market access preparations are underway for additional regions, including China, through a strategic partnership with Hansoh Pharmaceutical.
Expanding a high-impact therapeutic pipeline
In parallel with its commercial rollout, KiOmed Pharma is advancing innovative developments in aesthetic medicine and ophthalmology. The company has established a strategic partnership with Sinclair in the aesthetic sector and is developing a breakthrough treatment for dry eye syndrome utilizing its proprietary chitosan-based technology.
“We have built a well-balanced portfolio that integrates successfully a marketed product with strong clinical innovation,” said Houtaï Choumane, CEO of KiOmed Pharma. “This funding strengthens our ability to fulfill our mission of delivering transformative medical solutions that enhance patient outcomes worldwide.”
About KiOmed Pharma
Founded in 2014, KiOmed Pharma is a Belgian company specialised in the development of injectable medical devices based on a highly purified chitosan derivative of non-animal origin. A subsidiary of KitoZyme, the company focuses on three therapeutic areas: rheumatology, aesthetic medicine and ophthalmology, with the aim of addressing unmet clinical needs through safe and targeted medical solutions.
